Celebrating Mark Bamforth’s Appointment as Officer of the Order of the British Empire

Boston, MA, January 8, 2026 – We are pleased to share that Mark Bamforth, Executive Advisor at Ampersand Capital Partners, has been awarded an Order of the British Empire (OBE) in His Majesty King Charles III’s 2026 New Year Honours List, recognizing his contributions to UK Life Sciences and to strengthening UK–USA business relations.

This honor reflects Mark’s decades-long impact as a global life sciences leader and entrepreneur, advancing innovation in biomanufacturing and cell and gene therapy while building enduring transatlantic partnerships.

“Mark’s OBE, one of the highest service awards bestowed by the King in the United Kingdom, is a well-deserved recognition of a career defined by impact, integrity, and service to the life sciences industry,” said David Anderson, General Partner at Ampersand. “Having worked closely with Mark on the BrammerBio and ArrantaBio investments, I saw firsthand his ability to combine strategic vision with deep operational excellence. His leadership has shaped companies and lasting partnerships, and his influence at Ampersand and across the industry has been widely recognized.”

Mark and Ampersand have been working together for more than a decade, beginning with the BrammerBio partnership and continuing through ArrantaBio. Over this time, Mark has been a trusted partner to Ampersand and its portfolio companies, first as a Chief Executive Officer and now as an Executive Advisor. He currently serves as Executive Chair of the Board of Kincell Bio, a non-Ampersand portfolio company, and has founded and led several industry-leading CDMOs, including BrammerBio and ArrantaBio, both former Ampersand portfolio companies. Earlier in his career, Mark spent more than two decades at Genzyme, supporting the development of multiple products including cell therapies that led to the first FDA approval in the field.

In accepting the honor, Mark emphasized that the recognition reflects the collective efforts of colleagues and partners on both sides of the Atlantic and reaffirmed his commitment to advancing innovation and collaboration in life sciences.

We are proud to celebrate Mark’s achievement and grateful for the leadership and experience he continues to share with Ampersand. Congratulations, Mark, on this well-deserved honor.